BIOQUAL, Inc. (OTC-Pink:BIOQ) ( www.bioqual.com ):
Nine Months Ended |
| Three Months Ended | ||||||||||
| February 28, |
| February 29, |
| February 28, |
| February 29, | |||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 | |
Revenue | $ | 41,070,486 | $ | 32,884,055 | $ | 12,584,303 | $ | 11,593,217 | ||||
Income Before Income Tax | $ | 5,942,062 | $ | 4,150,830 | $ | 1,379,460 | $ | 1,018,306 | ||||
Net Income | $ | 4,203,962 | $ | 2,936,730 | $ | 975,960 | $ | 720,406 | ||||
Basic Earnings per Share |
|
|
|
|
|
|
|
| ||||
of Common Stock | $ | 4.70 | $ | 3.29 | $ | 1.09 | $ | .81 | ||||
Diluted Earnings per Share |
|
|
|
|
|
|
|
| ||||
of Common Stock | $ | 4.70 | $ | 3.29 | $ | 1.09 | $ | .81 | ||||
Weighted Average |
|
|
|
|
|
|
|
| ||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
| ||||
For Basic Earnings Per Share |
| 893,932 |
| 893,416 |
| 894,416 |
| 893,416 | ||||
Weighted Average |
|
|
|
|
|
|
|
| ||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
| ||||
For Diluted Earnings Per Share |
| 893,932 |
| 893,843 |
| 894,416 |
| 893,843 | ||||
For more detail related to the fiscal year 2021 unaudited third quarter results, please visit our web site at www.bioqual.com .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005716/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)